Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins

Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.